Ultragenyx Pharmaceutical Inc. 10-Q

Item 1. Financial Statements ULTRAGENYX PHARMACEUTICAL INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except share amounts) March 31, December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $ 383,794 $ 713,526 Marketable debt securities 581,614 488,007 Accounts receivable, net 25,032 23,093 Inventory 12,462 13,048 Prepaid expenses and other current assets 68,034 57,630 Total current assets 1,070,936 1,295,304 Property and equipment, net 87,570 73,515 Equity investments 134,756 155,375 Marketable debt securities 81,624 10,506 Right-of-use assets 38,511 40,524 Intangible assets, net 131,031 131,113 Goodwill 44,406 44,406 Other assets 8,929 8,812 Total assets $ 1,597,763 $ 1,759,555 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 15,744 $ 12,923 Accrued liabilities 82,699 108,491 Contract liabilities 19,221 59,219 Lease liabilities 9,380 8,976 Total current liabilities 127,044 189,609 Contract liabilities 5,868 7,349 Lease liabilities 36,752 39,251 Deferred tax liabilities 33,306 33,306 Liability related to the sale of future royalties 340,211 335,665 Total liabilities 543,181 605,180 Stockholders’ equity: Preferred stock — 25,000,000 shares authorized; nil outstanding as of March 31, 2021 and December 31, 2020 — — Common stock — 250,000,000 shares authorized; 67,439,477 and 66,818,520 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively 67 67 Additional paid-in capital 2,810,176 2,773,195 Accumulated other comprehensive income 56 689 Accumulated deficit ( 1,755,717 ) ( 1,619,576 ) Total stockholders’ equity 1,054,582 1,154,375 Total liabilities and stockholders’ equity $ 1,597,763 $ 1,759,555 See accompanying notes. 2 ULTRAGENYX PHARMACEUTICAL INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except share and per share amounts) Three Months Ended March 31, 2021 2020 Revenues: Collaboration and license $ 79,010 $ 27,215 Product sales 16,513 6,479 Non-cash collaboration royalty revenue 3,872 2,615 Total revenues 99,395 36,309 Operating expenses: Cost of sales 5,188 ( 3,503 ) Research and development 147,518 112,961 Selling, general and administrative 53,258 47,516 Total operating expenses 205,964 156,974 Loss from operations ( 106,569 ) ( 120,665 ) Interest income 639 2,919 Change in fair value of equity investments ( 20,619 ) 7,668 Non-cash interest expense on liability related to the sale of future royalties ( 8,418 ) ( 8,082 ) Other expense ( 795 ) ( 456 ) Loss before income taxes ( 135,762 ) ( 118,616 ) Provision for income taxes ( 379 ) ( 409 ) Net loss $ ( 136,141 ) $ ( 119,025 ) Net loss per share, basic and diluted $ ( 2.03 ) $ ( 2.05 ) Weighted-average shares used in computing net loss per share, basic and diluted 67,102,342 57,995,999 See accompanying notes. 3 ULTRAGENYX PHARMACEUTICAL INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) (In thousands) Three Months Ended March 31, 2021 2020 Net loss $ ( 136,141 ) $ ( 119,025 ) Other comprehensive loss: Foreign currency translation adjustments ( 285 ) ( 49 ) Unrealized loss on available-for-sale securities ( 348 ) ( 1,349 ) Other comprehensive loss ( 633 ) ( 1,398 ) Total comprehensive loss $ ( 136,774 ) $ ( 120,423 ) See accompanying notes. 4 ULTRAGENYX PHARMACEUTICAL INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) (In thousands, except share amounts) Common Stock Additional Paid-In Accumulated Other Comprehensive Accumulated Total Stockholders' Shares Amount Capital Income (Loss) Deficit Equity Balance as of December 31, 2020 66,818,520 $ 67 $ 2,773,195 $ 689 $ ( 1,619,576 ) $ 1,154,375 Stock-based compensation expense — — 24,220 — — 24,220 Issuance of common stock under equity plan awards, net of tax 620,957 — 12,761 — — 12,761 Other comprehensive loss — — — ( 633 ) — ( 633 ) Net loss — — — — ( 136,141 ) ( 136,141 ) Balance as of March 31, 2021 67,439,477 $ 67 $ 2,810,176 $ 56 $ ( 1,755,717 ) $ 1,054,582 Common Stock Additional Paid-In Accumulated Other Comprehensive Accumulated Total Stockholders' Shares Amount Capital Income (Loss) Deficit Equity Balance as of December 31, 2019 57,838,220 $ 58 $ 2,086,863 $ ( 147 ) $ ( 1,433,010 ) $ 653,764 Issuance of common stock in connection with license agreement, net of issuance costs 1,243,913 1 55,267 — — 55,268 Stock-based compensation expense — — 20,157 — — 20,157 Issuance of common stock upon exercise of warrants and under equity plan awards, net of tax 406,740 — 380 — — 380 Other comprehensive loss — — — ( 1,398 ) — ( 1,398 ) Net loss — — — — ( 119,025 ) ( 119,025 ) Balance as of March 31, 2020 59,488,873 $ 59 $ 2,162,667 $ ( 1,545 ) $ ( 1,552,035 ) $ 609,146 See accompanying notes. 5 ULTRAGENYX PHARMACEUTICAL INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (In thousands) Three Months Ended March 31, 2021 2020 Operating activities: Net loss $ ( 136,141 ) $ ( 119,025 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 24,254 20,155 Amortization of premium (discount) on marketable debt securities, net 940 ( 299 ) Depreciation and amortization 3,367 2,852 Change in fair value of equity investments 20,619 ( 7,668 ) Non-cash collaboration royalty revenue ( 3,872 ) ( 2,615 ) Non-cash interest expense on liability related to the sale of future royalties 8,418 8,082 Other 325 463 Changes in operating assets and liabilities: Accounts receivable ( 1,993 ) 3,500 Inventory 474 149 Prepaid expenses and other assets ( 10,656 ) ( 15,096 ) Receivable related to the Daiichi Sankyo license agreement — ( 125,550 ) Accounts payable, accrued, and other liabilities ( 23,602 ) ( 5,383 ) Contract liabilities ( 41,479 ) 145,283 Net cash used in operating activities ( 159,346 ) ( 95,152 ) Investing activities: Purchase of property and equipment ( 16,414 ) ( 14,096 ) Purchase of marketable debt securities ( 405,230 ) ( 285,229 ) Proceeds from sale of marketable debt securities 14,980 16,600 Proceeds from maturities of marketable debt securities 224,240 187,600 Net cash used in investing activities ( 182,424 ) ( 95,125 ) Financing activities: Proceeds from the issuance of common stock in connection with the license agreement, net — 55,268 Proceeds from the issuance of common stock from exercise of warrants and equity plan awards, net 12,761 380 Other ( 112 ) ( 33 ) Net cash provided by financing activities 12,649 55,615 Effect of exchange rate changes on cash ( 771 ) ( 623 ) Net decrease in cash, cash equivalents and restricted cash ( 329,892 ) ( 135,285 ) Cash, cash equivalents and restricted cash at beginning of period 726,294 436,244 Cash, cash equivalents and restricted cash at end of period $ 396,402 $ 300,959 Supplemental disclosures of non-cash information: Acquired lease liabilities arising from obtaining right-of-use assets $ — $ 7,397 See accompanying notes. 6 ULTRAGENYX PHARMACEUTICAL INC. Notes to Condensed Consolidated Financial Statements 1. Organization Ultragenyx Pharmaceutical Inc. (the Company) is a biopharmaceutical company incorporated in California on April 22, 2010. The Company subsequently reincorporated in the state of Delaware in June 2011. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company operates as one reportable segment. The Company has three commercially approved products. Crysvita® (burosumab) is approved in the United States by the U.S. Food and Drug Administration (FDA) and in Canada for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of age and older, and is approved in the European Union (EU) and the United Kingdom, for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older, adolescents, and adults. In Brazil and Mexico, Crysvita is approved for treatment of XLH in adult and pediatric patients one year of age and older. Crysvita is also approved in the United States by the FDA for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia (TIO), associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adults and pediatric patients 2 years of age and older. The Company has also received FDA approval for Mepsevii ® (vestronidase alfa), the first medicine approved for the treatment of children and adults with mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome. In the European Union and the United Kingdom, Mepsevii is approved under exceptional circumstances for patients of all ages for the treatment of non-neurological manifestations of MPS VII. In Brazil, Mepsevii is approved for the treatment of MPS VII for patients of all ages. Dojolvi ® , formerly known as UX007, is approved in the United States and Canada for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders (LC-FAOD). In addition to the approved products, the Company has the following ongoing clinical development programs: • DTX401 is an adeno-associated virus 8 (AAV8) gene therapy product candidate for the treatment of patients with glycogen storage disease type Ia (GSDIa); • DTX301 is an AAV8 gene therapy product candidate in development for the treatment of patients with ornithine transcarbamylase (OTC) deficiency, the most common urea cycle disorder; • UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway and inhibits the activity of bone-forming cells for the treatment of patients with osteogenesis imperfect (OI); • GTX-102 is an antisense oligonucleotide (ASO), which the Company is collaborating on the development with GeneTx Biotherapeutics LLC (GeneTx) for the treatment of Angelman syndrome, a debilitating and rare neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene; • UX701 is an AAV type 9 gene therapy designed to deliver stable expression of a truncated version of the ATP7B copper transporter following a single intravenous infusion to improve copper distribution and excretion from the body and reverse pathological findings of Wilson liver disease; and • UX053 is a messenger RNA (mRNA) product candidate designed for the treatment of patients with Glycogen Storage Disease Type III (GSDIII), a disease caused by a glycogen debranching enzyme (AGL) deficiency that results in glycogen accumulation in the liver and muscle. The Company has sustained operating losses and expects such annual losses to continue over the next several years. The Company’s ultimate success depends on the outcome of its research and development and commercialization activities, for which it expects to incur additional losses in the future. Management recognizes that the Company will need to raise additional capital to fully implement its business plans. Through March 31, 2021, the Company has relied primarily on its sale of equity securities, its sale of future royalties, and strategic collaboration arrangements, to finance its operations. The Company will likely raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans. 7 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying unaudited Condensed Consolidated financial Statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation. These financial statements should be read in conjunction with the audited financial statements and notes thereto for the preceding fiscal year contained in the Company’s Annual Report on Form 10-K filed on February 12, 2021 with the United States Securities and Exchange Commission (SEC). The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021. The Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from audited financial statements at that date, but does not include all of the information required by GAAP for complete financial statements. Use of Estimates The accompanying consolidated financial statements have been prepared in accordance with GAAP. The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, stock-based compensation, and the liability related to the sale of future royalties. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Cash, Cash Equivalents and Restricted Cash Restricted cash primarily consists of money market accounts used as collateral for the Company’s obligations under its facility leases and the gene therapy building construction project. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statement of cash flows (in thousands): March 31, 2021 2020 Cash and cash equivalents $ 383,794 $ 298,190 Restricted cash included in prepaid expenses and other current assets 10,687 161 Restricted cash included in other assets 1,921 2,608 Total cash, cash equivalents, and restricted cash shown in the statements of cash flows $ 396,402 $ 300,959 Credit Losses For trade receivables and other instruments, the Company uses a new forward-looking expected loss model that generally results in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses are recognized as allowances rather than as reductions in the amortized cost of the securities. The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company’s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company’s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers’ credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers’ current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the novel coronavirus (COVID-19) pandemic and determined that the estimate of credit losses was not significantly impacted. There was no material allowance recorded for losses on receivables and available-for-sale debt securities which were attributable to credit risk for the three months ended March 31, 2021 and 2020. 8 Revenue Recognition Collaboration and license revenue The Company has certain license and collaboration agreements that are within the scope of Accounting Standards Codification (ASC) 808, Collaborative Agreements , which provides guidance on the presentation and disclosure of collaborative arrangements. Generally, the classification of the transactions under the collaborative arrangements is determined based on the nature of contractual terms of the arrangement, along with the nature of the operations of the participants. The Company records its share of collaboration revenue, net of transfer pricing related to net sales in the period in which such sales occur, if the Company is considered as an agent in the arrangement. The Company is considered an agent when the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. Funding received related to research and development services and commercialization costs is generally classified as a reduction of research and development expenses and selling, general and administrative expenses, respectively, in the consolidated statement of operations, because the provision of such services for collaborative partners are not considered to be part of the Company’s ongoing major or central operations. In order to record collaboration revenue, the Company utilizes certain information from its collaboration partners , including revenue from the sale of the product, associated reserves on revenue, and costs incurred for development and sales activities. For the periods covered in the financial statements presented, there have been no material changes to prior period estimates of revenues and expenses. The Company sold the right to receive certain royalty payments from net sales of Crysvita to RPI Finance Trust (RPI), an affiliate of Royalty Pharma, as further described in Note 7. The Company records the royalty revenue from the net sales of Crysvita in the applicable European territories on a prospective basis as non-cash royalty revenue in the Consolidated Statements of Operations over the term of the arrangement. The terms of the Company’s collaboration and license agreements may contain multiple performance obligations, which may include licenses and research and development activities. The Company evaluates these agreements under ASC 606, Revenue from Contracts with Customers (ASC 606), to determine the distinct performance obligations. The Company analogizes to ASC 606 for the accounting for distinct performance obligations for which there is a customer relationship. Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Total consideration may include nonrefundable upfront license fees, payments for research and development activities, reimbursement of certain third-party costs, payments based upon the achievement of specified milestones, and royalty payments based on product sales derived from the collaboration. If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined based on the prices charged to customers or using expected cost-plus margin. The Company estimates the efforts needed to complete the performance obligations and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligations using input measures. Product sales The Company sells its approved products through a limited number of distributors. Under ASC 606, revenue from product sales is recognized at the point in time when the delivery is made and when title and risk of loss transfers to these distributors. The Company also recognizes revenue from sales of certain products on a “named patient” basis, which are allowed in certain countries prior to the commercial approval of the product. Prior to recognizing revenue, the Company makes estimates of the transaction price, including any variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Product sales are recorded net of estimated government-mandated rebates and chargebacks, estimated product returns, and other deductions. Provisions for returns and other adjustments are provided for in the period the related revenue is recorded, as estimated by management. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are reviewed periodically and adjusted as necessary. The Company’s estimates of government mandated rebates, chargebacks, estimated product returns, and other deductions depends on the identification of key customer contract terms and conditions, as well as estimates of sales volumes to different classes of payors. If actual results vary, the Company may need to adjust these estimates, which could have an effect on earnings in the period of the adjustment. 9 3. Financial Instruments Financial assets and liabilities are recorded at fair value. The carrying amount of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: Level 1 —Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; Level 2 —Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level 3 —Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. The Company determines the fair value of its equity investments in Arcturus Therapeutics Holdings Inc. (Arcturus) and Solid Biosciences Inc. (Solid) by using the quoted market prices, which are Level 1 fair value measurements. The following tables set forth the fair value of the Company’s financial assets remeasured on a recurring basis based on the three-tier fair value hierarchy (in thousands): March 31, 2021 Level 1 Level 2 Level 3 Total Money market funds $ 327,655 $ — $ — $ 327,655 Certificate of deposits and time deposits — 12,502 — 12,502 Corporate bonds — 204,050 — 204,050 Commercial paper — 286,498 — 286,498 Asset-backed securities — 51,659 — 51,659 U.S. Government Treasury and agency securities 75,796 42,809 — 118,605 Debt securities in government-sponsored entities — 15,259 — 15,259 Investments in Arcturus and Solid common stock 134,137 — — 134,137 Total $ 537,588 $ 612,777 $ — $ 1,150,365 December 31, 2020 Level 1 Level 2 Level 3 Total Money market funds $ 598,392 $ — $ — $ 598,392 Time deposits — 10,000 — 10,000 Corporate bonds — 193,802 — 193,802 Commercial paper — 173,859 — 173,859 Asset-backed securities — 11,225 — 11,225 U.S. Government Treasury and agency securities 167,967 17,661 — 185,628 Investments in Arcturus and Solid common stock 154,756 — — 154,756 Total $ 921,115 $ 406,547 $ — $ 1,327,662 In July 2020, the Company invested $ 2.5 million in a private diagnostic company, in the form of a convertible promissory note that matures in two years , if not converted earlier. The Company was also issued a warrant to purchase up to $ 1.0 million of the entity’s preferred stock. The fair value of the warrant to purchase shares of the entity was based on unobservable inputs that are significant to the measurement of the fair value of the asset and is supported by little or no market data; accordingly, the warrant is considered a Level 3 financial asset and is remeasured on a nonrecurring basis. The Company measured the fair value of the warrant by applying the Black-Scholes option pricing method and utilizing the following inputs: stock price, strike price, volatility, risk-free interest rate, and expected term. The Company recognizes the interest income on the convertible promissory note based on the effective interest rate method over the life of the note. As of March 31, 2021, the balance of the convertible promissory note was $ 2.1 million, including $ 0.3 million in interest receivable, and was recorded in other assets, and the allocated fair value of the warrant was $ 0.6 million and was recorded in investments in equity securities. In December 2020, the Company invested $ 1.4 million in Mazi Therapeutics, Inc. (Mazi), a private pharmaceutical company founded by a current employee of the Company, in the form of a convertible promissory note that matures in two years , if not converted earlier. As of March 31, 2021, the balance of the convertible promissory note was $ 1.4 million. 10 4. Balance Sheet Components Cash Equivalents and Investments The fair values of cash equivalents and investments classified as available-for-sale securities consisted of the following (in thousands): March 31, 2021 Gross Unrealized Amortized Cost Gains Losses Estimated Fair Value Money market funds $ 327,655 $ — $ — $ 327,655 Certificate of deposits and time deposits 12,502 — — 12,502 Corporate bonds 204,147 28 ( 125 ) 204,050 Commercial paper 286,498 — — 286,498 Asset-backed securities 51,678 1 ( 20 ) 51,659 U.S. Government Treasury and agency securities 118,566 39 — 118,605 Debt securities in government-sponsored entities 15,270 ( 11 ) 15,259 Total $ 1,016,316 $ 68 $ ( 156 ) $ 1,016,228 December 31, 2020 Gross Unrealized Amortized Cost Gains Losses Estimated Fair Value Money market funds $ 598,392 $ — $ — $ 598,392 Time deposits 10,000 — — 10,000 Corporate bonds 193,610 209 ( 17 ) 193,802 Commercial paper 173,859 — — 173,859 Asset-backed securities 11,224 1 — 11,225 U.S. Government Treasury and agency securities 185,561 67 — 185,628 Total $ 1,172,646 $ 277 $ ( 17 ) $ 1,172,906 At March 31, 2021, the remaining contractual maturities of available-for-sale securities were less than three years . There have been no significant realized gains or losses on available-for-sale securities for the three months ended March 31, 2021 and 2020. All marketable securities with unrealized losses at March 31, 2021 have been in a loss position for less than twelve months and were temporary in nature. We do not intend to sell the investments that are in an unrealized loss position before recovery of their amortized cost basis. Inventory Inventory consists of the following (in thousands): March 31, December 31, 2021 2020 Work-in-process $ 6,783 $ 7,184 Finished goods 5,679 5,864 Total inventory $ 12,462 $ 13,048 Accrued Liabilities Accrued liabilities consist of the following (in thousands): March 31, December 31, 2021 2020 Research, clinical study, and manufacturing expenses $ 23,456 $ 25,875 Payroll and related expenses 33,850 58,176 Other 25,393 24,440 Total accrued liabilities $ 82,699 $ 108,491 11 5. Revenue The following table disaggregates total revenues from customers (in thousands): Three Months Ended March 31, 2021 2020 Collaboration and license revenue: Crysvita collaboration revenue in profit-share territory $ 36,260 $ 27,215 Daiichi Sankyo 42,750 — Total collaboration and license revenue 79,010 27,215 Product sales: Crysvita 5,872 1,610 Mepsevii 3,607 3,425 Dojolvi 7,034 1,444 Total product sales 16,513 6,479 Crysvita non-cash collaboration royalty revenue 3,872 2,615 Total revenues $ 99,395 $ 36,309 The following table disaggregates total revenues based on geographic location (in thousands): Three Months Ended March 31, 2021 2020 North America $ 87,742 $ 30,357 Europe 5,637 4,157 All other 6,016 1,795 Total revenues $ 99,395 $ 36,309 The following table presents changes in the contract liabilities (in thousands): Three Months Ended March 31, 2021 2020 Balance of contract liabilities at beginning of period $ 66,568 $ — Additions 1,271 145,283 Deductions ( 42,750 ) — Balance of contract liabilities at end of period $ 25,089 $ 145,283 See Note 6 for additional details on contract liabilities activities. The Company’s largest accounts receivable balance accounted for 54 % and 71 % of the total accounts receivable balance as of March 31, 2021 and December 31, 2020, respectively, and was due from a collaboration partner. 6. License and Research Agreements Kyowa Kirin Collaboration and License Agreement In August 2013, the Company entered into a collaboration and license agreement with Kyowa Kirin Co., Ltd. (KKC, formerly Kyowa Hakko Kirin Co., Ltd. or KHK). Under the terms of this collaboration and license agreement, as amended, the Company and KKC collaborate on the development and commercialization of Crysvita in the field of orphan diseases in the United States and Canada, or the profit-share territory, and in the European Union, United Kingdom, and Switzerland, or the European territory, and the Company has the right to develop and commercialize such products in the field of orphan diseases in Mexico and Central and South America, or Latin America. Development Activities In the field of orphan diseases, and except for ongoing studies being conducted by KKC, the Company is the lead party for development activities in the profit-share territory and in the European territory until the applicable transition date. The Company shares the costs for development activities in the profit-share territory and the European territory conducted pursuant to the development plan before the applicable transition date equally with KKC. In April 2023, which is the transition date for the profit-share territory, KKC will become the lead party and be responsible for the costs of the development activities. However, the Company will continue to share the costs of the studies commenced prior to the applicable transition date equally with KKC. Crysvita was approved in the European Union and United Kingdom in February 2018 and was approved by the FDA in April 2018. 12 The collaboration and license agreements are within the scope of ASC 808, which provides guidance on the presentation and disclosure of collaborative arrangements. Collaboration revenue related to sales in profit-share territory The Company and KKC share commercial responsibilities and profits in the profit-share territory until April 2023. Under the collaboration agreement, KKC manufactures and supplies Crysvita for commercial use in the profit-share territory and charges the Company the transfer price of 35 % of net sales through December 31, 2022, and 30 % thereafter. The remaining profit or loss after supply costs from commercializing products in the profit-share territory are shared between the Company and KKC on a 50 /50 basis until April 2023. Thereafter, the Company will be entitled to receive a tiered double-digit revenue share in the mid-to-high 20 % range. As KKC is the principal in the sale transaction with the customer, the Company recognizes a pro-rata share of collaboration revenue, net of transfer pricing, in the period the sale occurs. The Company concluded that its portion of KKC’s sales in the profit-share territory is analogous to a royalty and therefore recorded its share as collaboration revenue, similar to a royalty. Royalty revenue related to sales in European territory KKC has the commercial responsibility for Crysvita in the European territory. In December 2019, the Company sold its right to receive royalty payments based on sales in the European territory to Royalty Pharma, effective January 1, 2020, as further described in Note 7. Prior to the Company’s sale of the royalty, the Company received a royalty of up to 10 % on net sales in the European territory, which was recognized as the underlying sales occur. Beginning in 2020, the Company recorded the royalty revenue as non-cash royalty revenues. The Company’s share of collaboration and royalty revenue related to Crysvita was as follows (in thousands): Three Months Ended March 31, 2021 2020 Company's share of revenue in profit-share territory $ 36,260 $ 27,215 Non-cash royalty revenue in European territory 3,872 2,615 Total $ 40,132 $ 29,830 Product revenue related to sales in other territories The Company is responsible for commercializing Crysvita in Latin America and Turkey. The Company is considered the principal in these territories as the Company controls the product before it is transferred to the customer. Accordingly, the Company records revenue on a gross basis related to the sale of Crysvita once the product is delivered and the risk and title of the product is transferred to the distributor. The Company recorded product sales of $ 5.9 million and $ 1.6 million for the three months ended March 31, 2021 and 2020 , respectively, net of estimated product returns and other deductions. KKC has the option to assume responsibility for commercialization efforts in Turkey from the Company, after a certain minimum period. Under the collaboration agreement, KKC manufactures and supplies Crysvita, which is purchased by the Company for sales in the above territories and is based on 35 % of the net sales through December 31, 2022 and 30 % thereafter. The Company also pays to KKC a low single-digit royalty on net sales in Latin America . Cost sharing payments Under the collaboration agreement, KKC and the Company share certain development and commercialization costs. As a result, the Company was reimbursed for these costs and operating expenses were reduced as follows (in thousands): Three Months Ended March 31, 2021 2020 Research and development $ 6,185 $ 5,490 Selling, general and administrative 7,495 7,052 Total $ 13,680 $ 12,542 Collaboration receivable and payable The Company had accounts receivable from KKC in the amount of $ 14.1 million and $ 16.4 million from profit-share revenue and royalties and other receivables recorded in prepaid and other current assets of $ 5.1 million and $ 9.6 million and accrued liabilities of $ 3.8 million and $ 2.4 million from commercial and development activity reimbursements, as of March 31, 2021 and December 31, 2020, respectively. Bayer HealthCare LLC The Company has an agreement with Bayer Healthcare LLC (Bayer) to research, develop and commercialize AAV gene therapy products for the treatment of hemophilia A (DTX 201). Under this agreement, Bayer has been granted an exclusive license to develop and commercialize one or more novel gene therapies for hemophilia A. The agreement requires that Bayer use commercially 13 reasonable efforts to conduct and fund a proof-of-concept (POC) clinical trial and any subsequent clinical trials and commercialization of gene therapy products for treatment of hemophilia A. Bayer has worldwide rights to commercialize the potential future product. Bayer was responsible for funding certain research and development services performed by the Company in the performance of its obligations under the annual research plan and budget. Under the terms of the agreement, the Company is eligible to receive development and commercialization milestone payments of up to $ 232.0 million, as well as, royalty payments ranging in the high single-digit to low double-digit percentages, not exceeding the mid-teens, of net sales of licensed products. The Company achieved the first milestone in December 2017, the second milestone in April 2018, and has received $ 15.0 million for such milestones to date. The Company has no further obligations under the contract. The Company may record future milestone payments as revenue, if it becomes probable that a significant reversal in the amount of revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Arcturus The Company has a Research Collaboration and License Agreement with Arcturus to research and develop therapies for select rare diseases. For the three months ended March 31, 2021 and 2020 , there were no research and development expenses incurred for the funding of certain research services received from Arcturus. In May 2020, the Company exercised an option to purchase 600,000 shares of Arcturus’ common stock at $ 16.00 per share, or a total purchase price of $ 9.6 million. In December 2020, the Company sold 800,000 shares of Arcturus’ common stock at a weighted-average price of $ 100.81 per share and received net proceeds of $ 79.8 million. The Company has elected to apply the fair value option to account for the equity investment in Arcturus. As of March 31, 2021, the Company held 2,200,000 shares of Arcturus’ common stock. The changes in the fair value of the Company’s equity investment in Arcturus securities were as follows (in thousands): Arcturus common stock Option to purchase additional shares of Arcturus common stock Total December 31, 2019 $ 26,088 $ 1,664 $ 27,752 Change in fair value 113,978 23,948 137,926 Transfer of value upon option exercise 35,212 ( 25,612 ) 9,600 Sale of shares ( 79,842 ) — ( 79,842 ) December 31, 2020 95,436 — 95,436 Change in fair value ( 4,576 ) — ( 4,576 ) March 31, 2021 $ 90,860 $ — $ 90,860 The Company recorded $ 4.6 million in unrealized loss and $ 7.7 million in unrealized gain for the three months ended March 31, 2021 and 2020, respectively, from the fair value adjustments on the equity investment in Arcturus securities. GeneTx In August 2019, the Company entered into a Program Agreement and a Unitholder Option Agreement with GeneTx to collaborate on the development of GeneTx’s GTX-102, an ASO for the treatment of Angelman syndrome. Pursuant to the terms of the Unitholder Option Agreement, the Company made an upfront payment of $ 20.0 million for an exclusive option to acquire GeneTx, which was exercisable any time prior to 30 days following FDA acceptance of the IND for GTX-102. Pursuant to the agreement, upon acceptance of the IND, which occurred in January 2020, the Company elected to extend the option period by paying an option extension payment of $ 25.0 million (option extension premium) during the quarter ended March 31, 2020. The Company has the right to acquire GeneTx for a payment of $ 125.0 million, at any time, until the earlier of 30 months from the first dosing of a patient in a planned Phase 1/2 study (subject to extensions) or 90 days after results are available from that study. This exclusive option to acquire GeneTx can be extended under certain circumstances, by up to four additional three-month periods, by paying an additional extension fee for each three-month period. During the exclusive option period, GeneTx is responsible for conducting the program based on the development plan agreed between the parties and, subject to the terms in the Program Agreement, has the decision-making authority on all matters in connection with the research, development, manufacturing and regulatory activities with respect to the Program. The Company will provide support, at its discretion, including strategic guidance and clinical expertise. The Company and GeneTx will collaborate on the management of the Phase 1/2 study in patients with Angelman syndrome. If the Company acquires GeneTx, the Company will then be responsible for all development and commercialization activities from the date of acquisition. The Company would also be required to make payments upon achievement of certain development and commercial milestones, as well as royalties, depending upon the success of the program. Although GeneTx is a variable interest entity, the Company is not the primary beneficiary as it currently does not have the power to direct the activities that would most significantly impact the economic performance of GeneTx. Prior to product regulatory approval, all consideration paid to GeneTx represents rights to potential future benefits associated with GeneTx’s in-process research 14 and development activities, which have not reached technological feasibility and have no alternative future use. Accordingly, for the three months ended March 31 , 2020, the Company recorded the option extension payment of $ 25.0 million as an in-process research and development expense. REGENXBIO, Inc. In March 2020, the Company executed a License Agreement with REGENXBIO, Inc. (REGENEX), for an exclusive, sublicensable, worldwide license to REGENX’s NAV AAV8 and AAV9 Vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder. In return for these rights, the Company made an upfront payment of $ 7.0 million, which was recorded as an in-process research and development expense during the three months ended March 31, 2020. The Company will pay certain annual fees of $ 0.1 million, milestone payments of up to $ 14.0 million, and royalties on any net sales of products incorporating the licensed intellectual property that range from a high single-digit to low double-digit royalty . Daiichi Sankyo In March 2020, the Company executed a License and Technology Access Agreement (the License Agreement) with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo). Pursuant to the License Agreement, the Company granted Daiichi Sankyo a non-exclusive license to intellectual property, including know-how and patent applications, with respect to its HeLa PCL and HEK293 transient transfection manufacturing technology platforms for AAV-based gene therapy products. The Company retains the exclusive right to use the manufacturing technology for its current target indications and additional indications identified now and in the future. The Company will provide certain technical assistance and technology transfer services during the technology transfer period of three years to enable Daiichi Sankyo to use the technologies for its internal gene therapy programs. Daiichi Sankyo has an option to extend the technology transfer period including know-how improvements by two additional one-year periods by paying a fixed amount for each additional year. Daiichi Sankyo will be responsible for the manufacturing, development, and commercialization of products manufactured with the licensed technology; however, the Company has the option to co-develop and co-commercialize rare disease products at the IND stage. Ultragenyx may also provide strategic consultation to Daiichi Sankyo on the development of both AAV-based gene therapy products and other products for rare diseases. Under the terms of the License Agreement, Daiichi Sankyo made an upfront payment of $ 125.0 million and will pay an additional $ 25.0 million upon completion of the technology transfer of the HeLa PCL and HEK293 platforms, as well as single-digit royalties on net sales of products manufactured in either system. Daiichi Sankyo will reimburse the Company for all costs associated with the transfer of the manufacturing technology. The Company also entered into a Stock Purchase Agreement (SPA) with Daiichi Sankyo, pursuant to which Daiichi Sankyo purchased 1,243,913 shares of the Company’s common stock in exchange for $ 75.0 million in cash during the first quarter of 2020. The fair market value of the common stock issued to Daiichi Sankyo was $ 55.3 million based on the stock price of $ 44.43 per share on the date of issuance, resulting in a $ 19.7 million premium on the SPA. Daiichi Sankyo is also subject to a three-year standstill and restrictions on sale of the shares (subject to customary exceptions or release). In June 2020, the Company executed a subsequent license agreement (the Sublicense Agreement) with Daiichi Sankyo for transfer of certain technology in consideration for an upfront payment of $ 8.0 million and annual maintenance fees, milestone payments, and royalties on any net sales of products incorporating the licensed intellectual property. The License Agreement, the Sublicense Agreement, and the SPA are being accounted for as one arrangement because they were entered into at or near the same time and negotiated in contemplation of one another. The Company evaluated the License Agreement and the Sublicense Agreement under ASC 606 and determined that the performance obligations under the agreements are (i) intellectual property with respect to its HeLa PCL and HEK293 transient transfection manufacturing technology platforms together with the initial technical assistance and technology transfer services, which are expected to be completed in the fourth quarter of 2021, and (ii) the transfer of any know-how and improvements after the completion of the initial technology transfer through the end of the three year technology transfer period ending March 2023. The Company determined that the total transaction price of the License Agreement was $ 183.4 million which was comprised of the $ 19.7 million premium from the SPA, the $ 125.0 million upfront payment, the $ 25.0 million in unconstrained milestone payments, $ 8.0 million from the Sublicense Agreement, and the $ 5.7 million estimated reimbursement amount for delivering the license and technology services. Total revenue recognized under the license agreement through March 31, 2021 is $ 132.0 million. 15 The Company allocated the total transaction price to the two performance obligations on a relative stand-alone selling price basis. Revenue allocated to the intellectual property and the technology transfer services will be recognized over an initial period which is estimated to end in the fourth quarter of 2021, measuring the progress toward complete satisfaction of the individual performance obligation using an input measure. Revenue for know-how and improvements after the completion of technology transfer will be recognized on a straight-line basis over the remaining technology transfer period , which ends in March 2023 , as it is expected that Daiichi Sankyo will receive and consume the benefits consistently throughout the period. The estimated period to complete the technology transfer services and the related milestones payments, if any, are subject to revised estimates which could be impacted by limitations or delays from the COVID-19 pandemic, successful scale-up of the manufacturing, and other changes that may impact timing. Royalties from commercial sales will be accounted for as revenue upon achievement of such sales, assuming all other revenue recognition criteria are met. For the three months ended March 31, 2021 and 2020, the Company recognized $ 42.8 million and none , respectively, in revenue related to this arrangement. Accordingly, the Company had recorded $ 25.1 million as contract liabilities, net, as of March 31, 2021 . The Company recorded an accounts receivable related to the above agreements of $ 1.3 million as of March 31, 2021. Solid Biosciences, Inc. In October 2020, the Company entered into a strategic Collaboration and License Agreement with Solid Biosciences Inc., or Solid, and received an exclusive license for any pharmaceutical product that expresses Solid’s proprietary microdystrophin construct from AAV8 and variants thereof in clade E for use in the treatment of Duchenne muscular dystrophy and other diseases resulting from lack of functional dystrophin, including Becker muscular dystrophy. The Company will collaborate to develop products that combine Solid’s differentiated microdystrophin construct, the Company’s HeLa PCL manufacturing platform, and the Company’s AAV8 variants. Solid will also provide development support and was granted an exclusive option to co-invest in products the Company develops for profit share participation in certain territories. On a product-by-product basis, the Company may be obligated to make development milestone payments of up to $ 25.0 million, regulatory milestone payments of up to $ 65.0 million, and commercial milestone payments of up to $ 165.0 million, if such milestones are achieved, as well as royalties on any net sales of products incorporating the licensed intellectual property that range from a low to mid-double-digit percentage. The royalty rate changes to mid to high double-digit percentage if Solid decides to co-invest in the product. The Company also entered into a Stock Purchase Agreement and the Investor Agreement with Solid, pursuant to which, the Company purchased 7,825,797 shares of Solid’s common stock for an aggregate purchase price of $ 40.0 million. Subject to the terms of the Investor Agreement, the Company is restricted from selling, transferring or otherwise disposing of the shares without the prior approval of Solid until the earlier of (i) 18 months following the closing of the transaction, (ii) the termination of the Collaboration and License Agreement and (iii) certain other specified events. The Company also agreed to customary standstill restrictions in accordance with the terms of the Investor Agreement until the earlier of (a) 24 months after the closing of the transaction and (b) certain specified events. The Company’s investment in Solid is being accounted at fair value, as the fair value is readily determinable. The Company recorded the common stock investment at $ 26.8 million on the transaction date, which was based on the quoted market price on the closing date. Although Solid is a variable interest entity, the Company is not the primary beneficiary as it does not have the power to direct the activities that would most significantly impact the economic performance of Solid. Prior to the achievement of certain development milestones, all consideration paid to Solid represents rights to potential future benefits associated with Solid’s in-process research and development activities, which have not reached technological feasibility and have no alternative future use. Accordingly, the remaining $ 13.2 million of the total $ 40.0 million paid as consideration was attributed to the license rights obtained and was recorded as in-process research and development expense during the year ended December 31, 2020. The changes in the fair value of the Company’s investment in Solid’s common stock were as follows (in thousands): Solid common stock Acquisition of investment in Solid common stock in October 2020 $ 26,843 Change in fair value 32,477 December 31, 2020 59,320 Change in fair value ( 16,043 ) March 31, 2021 $ 43,277 16 Mereo BioPharma 3 Limited In December 2020, the Company entered into a License and Collaboration Agreement with Mereo BioPharma 3 Limited, or Mereo, to collaborate on the development of setrusumab. Under the terms of the agreement, the Company will lead future global development of setrusumab in both pediatric and adult patients with Osteogenesis Imperfecta, or OI. The Company was granted an exclusive license to develop and commercialize setrusumab in the U.S., Turkey, and the rest of the world, excluding the European Economic Area, United Kingdom, and Switzerland, or the Mereo territory, where Mereo retains commercial rights. Each party will be responsible for post-marketing commitments and commercial supply in their respective territories. Upon the closing of the transaction in January 2021, the Company made a payment of $ 50.0 million to Mereo and will be required to make payments of up to $ 254.0 million upon the achievement of certain clinical, regulatory, and commercial milestones. The Company will pay for all global development costs as well as tiered double-digit percentage royalties to Mereo on net sales in the U.S., Turkey, and the rest of the world (excluding the Mereo Territory), and Mereo will pay the Company a fixed double-digit percentage royalty on net sales in the Mereo Territory. Although Mereo is a variable interest entity, the Company is not the primary beneficiary as it does not have the power to direct the activities that would most significantly impact the economic performance of Mereo. Prior to the achievement of certain development milestones, all consideration paid to Mereo represents rights to potential future benefits associated with Mereo’s in-process research and development activities, which have not reached technological feasibility and have no alternative future use. Accordingly, for the three months ended March 31, 2021, the Company recorded the upfront payment of $ 50.0 million as in-process research and development expense. 7. Liability Related to the Sale of Future Royalties In December 2019, the Company entered into a Royalty Purchase Agreement with RPI. Pursuant to the agreement, RPI paid $ 320.0 million to the Company in consideration for the right to receive royalty payments effective January 1, 2020, arising from the net sales of Crysvita in the European Union, the United Kingdom, and Switzerland under the terms of the Company’s Collaboration and License Agreement with KKC dated August 29, 2013, as amended. The agreement with RPI will automatically terminate, and the payment of royalties to RPI will cease, in the event aggregate royalty payments received by RPI are equal to or greater than $ 608.0 million prior to December 31, 2030, or in the event aggregate royalty payments received by RPI are less than $ 608.0 million prior to December 31, 2030, when aggregate royalty payments received by RPI are equal to $ 800.0 million. Proceeds from the transaction were recorded as a liability (liability related to sale of future royalties on the Consolidated Balance Sheets). The Company amortizes $ 320.0 million, net of transaction cost of $ 5.8 million using the effective interest method over the estimated life of the arrangement. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty payments to be received by the Company and paid to RPI, subject to the capped amount, over the life of the arrangement. The excess of future estimated royalty payments (subject to the capped amount), over the $ 314.2 million of net proceeds, is recorded as non-cash interest expense over the life of the arrangement. Consequently, the Company estimates an imputed interest on the unamortized portion of the liability and records interest expense relating to the transaction. The Company records the royalty revenue arising from the net sales of Crysvita in the applicable European territories as non-cash royalty revenue in the Consolidated Statements of Operations over the term of the arrangement. The Company periodically assesses the expected royalty payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company’s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. The Company’s effective annual interest rate was approximately 9.8 % for the three months ended March 31, 2021. There are a number of factors that could materially affect the amount and timing of royalty payments from KKC in the applicable European territories, most of which are not within the Company’s control. Such factors include, but are not limited to, the success of KKC’s sales and promotion of Crysvita, changing standards of care, delays or disruptions related to the COVID-19 pandemic, the introduction of competing products, pricing for reimbursement in various European territories, manufacturing or other delays, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of Crysvita, significant changes in foreign exchange rates as the royalty payments are made in U.S. dollars (USD) while significant portions of the underlying European sales of Crysvita are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from European sales of Crysvita, all of which would result in a reduction of non-cash royalty revenue and the non-cash interest expense over the life of the arrangement. Conversely, if sales of Crysvita in Europe are more than expected, the non-cash royalty revenue and the non-cash interest expense recorded by the Company would be greater over the term of the arrangement. The following table shows the activity within the liability account (in thousands): 17 Liability related to the sale of future royalties December 31, 2019 $ 315,369 Non-cash collaboration royalty revenue ( 12,995 ) Non-cash interest expense 33,291 December 31, 2020 335,665 Non-cash collaboration royalty revenue ( 3,872 ) Non-cash interest expense 8,418 March 31, 2021 $ 340,211 8 . Stock-Based Awards The 2014 Incentive Plan (the 2014 Plan) provides for automatic annual increases in shares available for grant, beginning on January 1, 2015 through January 1, 2024 . As of March 31, 2021, there were 4,192,549 shares reserved under the 2014 Plan for the future issuance of equity awards, 3,995,536 shares reserved for the 2014 Employee Stock Purchase Plan, and 500,000 shares reserved for the Employment Inducement Plan. The table below sets forth the stock-based compensation expense for the periods presented (in thousands): Three Months Ended March 31, 2021 2020 Cost of sales $ 379 $ 68 Research and development 13,489 10,929 Selling, general and administrative 10,430 9,175 Total stock-based compensation expense $ 24,298 $ 20,172 9 . Net Loss Per Share Basic net loss per share has been computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period. The following weighted-average outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: Three Months Ended March 31, 2021 2020 Options to purchase common stock and restricted stock units 8,084,585 8,404,411 Employee stock purchase plan 33,636 62,434 Common stock warrants — 118,444 8,118,221 8,585,289 10 . Equity Transactions In October 2020, the Company completed an underwritten public offering in which 5,111,110 shares of common stock were sold, which included 666,666 shares purchased by the underwriters pursuant to an option granted to them in connection with the offering, at a public offering price of $ 90.00 per share. For the year ended December 31, 2020, the total proceeds that the Company received from the offering were approximately $ 435.6 million, net of underwriting discounts and commissions. 11 . Accumulated Other Comprehensive Income Total accumulated other comprehensive income consisted of the following (in thousands): March 31, December 31, 2021 2020 Foreign currency translation adjustments $ 144 $ 429 Unrealized gain (loss) on available-for-sale securities ( 88 ) 260 Total accumulated other comprehensive income $ 56 $ 689 18